Study wrapper · #1328
Impact of surfactants on the stability of therapeutic peptides under interfacial stress.
Editor's note
A laboratory formulation study, not a clinical one, but it speaks directly to a question peptide readers care about: what actually happens to a peptide solution under agitation stress. The methods are appropriate — size-exclusion chromatography, circular dichroism, and NMR converging on the same mechanistic story — though liraglutide is the primary model and semaglutide only an exploratory comparison, so the semaglutide finding is a single-condition observation rather than a characterised profile. The relative robustness of semaglutide's oligomers is consistent with its commercial formulation. Nothing here should be extrapolated to reconstituted or repackaged material, which faces different stresses entirely.
Plain-language abstract
Formulation scientists shook peptide solutions to mimic the stress of shipping and handling, then measured how three common stabilising surfactants affected clumping. The results were strongly molecule-specific: liraglutide aggregated badly in the presence of polysorbate 80 and poloxamer 188, semaglutide barely changed because its oligomers are intrinsically more stable, and glucagon fibrillated regardless. The general lesson is that a surfactant that stabilises an antibody can destabilise a flexible peptide, so additives cannot be assumed to help by default.